Predicting Non-AIDS Comorbidity and Mortality in HIV: Insights from a Recent Study

Sun Oct 01 2017

In the dynamic realm of HIV research, a recent study has cast a revealing light on a potential game-changer. The study titled “Predicting Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection through Soluble Urokinase Plasminogen Activator Receptor” published in The Journal of Infectious Diseases takes us beyond the traditional HIV narrative, exploring non-AIDS comorbidities and overall mortality.

Chronic inflammation and persistent immune activation have emerged as pivotal factors linked to the progression of non-AIDS-related health issues and mortality in individuals living with HIV. The study delves into the soluble urokinase plasminogen activator receptor (suPAR) as a potential prognostic marker. It investigates the relationship between suPAR levels and the incidence of non-AIDS comorbidities, along with overall mortality risk, within a carefully managed HIV-positive population.

The study’s findings are both compelling and enlightening. A notable revelation is the direct and independent correlation between suPAR levels at baseline and increased hazard rates. These elevated rates extend their influence over various non-AIDS comorbidities including cardiovascular disease, chronic kidney disease, chronic lung disease, liver ailments, and even the specter of cancer. This suggests that suPAR might serve as an unexpected indicator of an array of health challenges for individuals dealing with HIV.

In essence, the study sheds light on the intricate interplay between inflammation, suPAR, and the complex landscape of non-AIDS comorbidities and mortality. As we delve deeper into this aspect of HIV research, there’s potential for refining risk assessment, interventions, and patient care—an essential step toward the holistic well-being of people with HIV. While we anticipate further progress in this field, it’s evident that even the smallest molecular interactions can create profound ripples in the lives of those navigating the intricacies of HIV.


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPARnostic POC+


Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates